SCHEDULE: Woodline Partners Reports 4.4% Stake in Quoin Pharmaceuticals

Woodline Partners LP has disclosed a beneficial ownership of 4.4% of Quoin Pharmaceuticals, Ltd.'s ordinary shares, holding 2,785,370 shares as of March 31, 2026.

Summary

• Woodline Partners LP, acting as the investment adviser to Woodline Master Fund LP, has filed a Schedule 13G indicating beneficial ownership of Quoin Pharmaceuticals, Ltd. ordinary shares.
• The filing reports 2,785,370 ordinary shares beneficially owned by Woodline Partners LP, representing 4.4% of the class.
• These shares are held indirectly through the Woodline Fund, which holds American Depositary Shares (ADSs) of Quoin Pharmaceuticals.
• The filing date for this event is March 31, 2026.
• The total number of ordinary shares outstanding as of March 23, 2026, was 63,126,930, as reported in Quoin Pharmaceuticals' Form 10-K filed on March 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance data for Quoin Pharmaceuticals.

Positives

• Woodline Partners LP has publicly disclosed its significant stake, providing transparency to the market regarding its investment in Quoin Pharmaceuticals.
• The filing indicates a substantial investment, potentially signaling confidence in the company's future prospects from a notable investment firm.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures inherent in a Schedule 13G filing.
• Potential risks for Quoin Pharmaceuticals could include market volatility, regulatory changes, and competitive pressures, though these are not detailed in this specific filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific future outlook for Quoin Pharmaceuticals.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors acquiring more than 5% of a company's stock. Woodline Partners LP's filing indicates a significant passive investment in Quoin Pharmaceuticals, a company operating in the biotechnology or pharmaceutical sector, which is often characterized by high growth potential and significant R&D investment.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, potentially influencing market perception and trading activity.
• Management: Awareness of a significant passive investor, which may influence strategic decisions or future engagement.
• Potential Investors: Provides information on the ownership structure and the presence of institutional capital.

Next Steps

• Monitor future filings from Woodline Partners LP for any changes in their stake.
• Observe Quoin Pharmaceuticals' operational and financial performance for insights into the company's strategy and growth.

Key Dates

Keywords

Schedule 13G, Woodline Partners LP, Quoin Pharmaceuticals, beneficial ownership, ordinary shares, ADSs, investment adviser, SEC filing, QNRX